The University of Southampton
University of Southampton Institutional Repository

Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas

Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas
Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas
INTRODUCTION: In vivo labelling of human breast tumours with bromodeoxyuridine (BrdUrd) and analysis by flow cytometry (FCM) allows the labelling index (LI), S phase duration (t(s)) and the potential doubling time (t(pot)) of the tumour to be estimated.

METHODS: The data for a series of tumour specimens from 75 patients with invasive breast carcinoma were reported in 1991, correlated with their lymph-node status, tumour size and grade.

RESULTS AND CONCLUSIONS: This study reports the follow-up data over 10 years in respect of time to recurrence and death from the disease. There were no significant correlations between proliferation data and outcome measures. No adverse events were identified which could be attributed to the use of the halogenated pyrimidine label in vivo.
breast cancer, bromodeoxyuridine, recurrence, outcome
0748-7983
747-750
Cutress, R. I.
68ae4f86-e8cf-411f-a335-cdba51797406
Mullee, M. A.
243e4a43-2dd4-463d-8b88-c2b5d4bfe608
Royle, G. T.
1fdbdd22-5cfe-4b4b-815a-12a229debe36
Rew, D. A.
31d154a0-2ef4-4685-b74c-88a3c6451cf8
Cutress, R. I.
68ae4f86-e8cf-411f-a335-cdba51797406
Mullee, M. A.
243e4a43-2dd4-463d-8b88-c2b5d4bfe608
Royle, G. T.
1fdbdd22-5cfe-4b4b-815a-12a229debe36
Rew, D. A.
31d154a0-2ef4-4685-b74c-88a3c6451cf8

Cutress, R. I., Mullee, M. A., Royle, G. T. and Rew, D. A. (2000) Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas. European Journal of Surgical Oncology, 26 (8), 747-750. (doi:10.1053/ejso.2000.0997). (PMID:11087639)

Record type: Article

Abstract

INTRODUCTION: In vivo labelling of human breast tumours with bromodeoxyuridine (BrdUrd) and analysis by flow cytometry (FCM) allows the labelling index (LI), S phase duration (t(s)) and the potential doubling time (t(pot)) of the tumour to be estimated.

METHODS: The data for a series of tumour specimens from 75 patients with invasive breast carcinoma were reported in 1991, correlated with their lymph-node status, tumour size and grade.

RESULTS AND CONCLUSIONS: This study reports the follow-up data over 10 years in respect of time to recurrence and death from the disease. There were no significant correlations between proliferation data and outcome measures. No adverse events were identified which could be attributed to the use of the halogenated pyrimidine label in vivo.

Full text not available from this repository.

More information

Published date: December 2000
Keywords: breast cancer, bromodeoxyuridine, recurrence, outcome
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 352085
URI: https://eprints.soton.ac.uk/id/eprint/352085
ISSN: 0748-7983
PURE UUID: 9ac20a8f-6591-4e25-ae23-e2f98e9c1127

Catalogue record

Date deposited: 01 May 2013 11:51
Last modified: 18 Jul 2017 04:19

Export record

Altmetrics

Contributors

Author: R. I. Cutress
Author: M. A. Mullee
Author: G. T. Royle
Author: D. A. Rew

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×